focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,753.00
Ask: 1,754.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.057%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Astrazeneca leads FTSE higher on bid speculation

Thu, 21st Aug 2014 17:42

- Healthcare stocks lift FTSE- German PMI data drives sentiment- Investors look ahead to Draghi speech- UK retail sales disappointtechMARK 2,819.77 +0.82%FTSE 100 6,777.66 +0.33%FTSE 250 15,838.57 +0.57%London's blue chips ended Thursday's session on a positive note, led by Astrazeneca. Increased speculation regarding ECB action, on the heels of weaker than forecast readings on the Eurozone economy, were offset by a weak report on UK retail sales. After making gains both early and late on, the FTSE 100 ultimately closed 22 points higher at 6,778. July saw UK retail sales register their slowest annual gain since November, with volumes surprising with a slowdown to just a 0.1% rate of gain, compared to an advance of 0.2% in June. Expectations had been for a rise of 0.4%. Investors were also surprised to see that food sales declined, the first time on record that this has happened. The Office for National Statistics also released figures showing that while UK public finances improved last month borrowing still remained above the government's target.Across the Channel, Markit's 'flash' composite Purchasing Managers' Index (PMI), which tracks growth in the manufacturing and service sectors that make up more than two-thirds of the economy, fell to 54.9 in August from 55.7. However, it nonetheless remained well above the crucial 50 mark that separates growth from contraction.On the upside, Germany's private sector grew for a 16th month running in August, suggesting Europe's largest economy could expand robustly in the third quarter after it suffered a surprise contraction in the second.However, following those figures Barclays Research pointed out that it sees "material downside risks" to its forecast for the Eurozone's GDP to expand at 0.3% quarter-on-quarter clip in the third quarter. Meanwhile, the Jackson Hole Symposium of central bankers is due to kick off later Stateside with comments from policymakers around the world likely to be closely watched.Bid speculation sends Astrazeneca racing aheadHealthcare stocks gained strongly amid speculation Pfizer may make another bid for Astrazeneca. Smith & Nephew and GlaxoSmithKline also rose strongly. Financial stocks also made decent gains, with Hargreaves Lansdown, Standard Life, Old Mutual and Aviva all higher. Mining stocks led to the downside after metals consumer China disappointed with its manufacturing data and metals prices fell. Fresnillo, Randgold Resources, Anglo American, Rio Tinto and BHP Billiton all fell into the red. BHP was still under pressure in the aftermath of Tuesday's underwhelming plans for a demerger. Chief financial officer Graham Kerr, who is due to be the head of the spin-off company, has been cited as saying that the lack of a share buyback - which many investors had been expecting - was a "sore point", while plans to give shareholders stock in the new firm may have "irritated" some who are not mandated to hold investments in Australia. Oil stock Tullow Oil was also in the red. On the second tier, metal miner Kazakhmys hailed progress with a shake-up designed to focus it on the lucrative copper market, but said 2014 gold production was likely to fall short of hopes, pushing the stock into the red. Investec knocked Ophir Energy lower after it reduced its rating to 'hold' from 'buy' and lowered its target price to 250p from 315p.FTSE 100 - RisersAstraZeneca (AZN) 4,411.50p +2.95%Schroders (SDR) 2,392.00p +2.66%Hargreaves Lansdown (HL.) 1,133.00p +2.16%CRH (CRH) 1,401.00p +2.04%Barratt Developments (BDEV) 366.20p +1.84%Smith & Nephew (SN.) 1,064.00p +1.62%3i Group (III) 387.60p +1.57%Standard Life (SL.) 376.90p +1.48%Mondi (MNDI) 1,018.00p +1.39%Rolls-Royce Holdings (RR.) 1,037.00p +1.37%FTSE 100 - FallersFresnillo (FRES) 938.00p -3.55%Randgold Resources Ltd. (RRS) 4,904.00p -1.86%Kingfisher (KGF) 306.80p -1.67%Anglo American (AAL) 1,573.50p -1.29%Antofagasta (ANTO) 808.50p -1.28%Royal Mail (RMG) 440.30p -1.21%Petrofac Ltd. (PFC) 1,126.00p -1.14%easyJet (EZJ) 1,324.00p -1.12%Aberdeen Asset Management (ADN) 431.70p -1.10%Rio Tinto (RIO) 3,433.00p -0.72%FTSE 250 - RisersSenior (SNR) 292.40p +3.84%Hikma Pharmaceuticals (HIK) 1,742.00p +2.96%Ocado Group (OCDO) 377.90p +2.89%Phoenix Group Holdings (DI) (PHNX) 735.50p +2.87%RPS Group (RPS) 269.50p +2.86%Cranswick (CWK) 1,349.00p +2.82%International Personal Finance (IPF) 520.00p +2.77%Diploma (DPLM) 686.00p +2.62%Spirent Communications (SPT) 103.50p +2.48%Carillion (CLLN) 337.60p +2.30%FTSE 250 - FallersKazakhmys (KAZ) 291.10p -5.64%Petra Diamonds Ltd.(DI) (PDL) 183.60p -3.72%Ophir Energy (OPHR) 221.40p -3.61%Exova Group (EXO) 220.00p -3.51%Just Retirement Group (JRG) 146.20p -2.60%Thomas Cook Group (TCG) 121.00p -2.42%Electrocomponents (ECM) 239.80p -2.36%Ladbrokes (LAD) 132.30p -2.22%Lonmin (LMI) 212.90p -2.11%African Barrick Gold (ABG) 239.60p -1.80%AB
More News
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 08:49

GSK's depemokimab asthma treatment meets endpoints in latest trials

(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatment options for patients with severe asthma.

Read more
21 May 2024 07:21

GSK reports promising results from asthma treatment trials

(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.

Read more
20 May 2024 16:11

IN BRIEF: GSK executive buys GBP20,026 worth shares

GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares at 1,788 pence each. Worth total GBP20,026.

Read more
17 May 2024 17:38

London's FTSE nudges lower for week after record run

Haleon falls after GSK offloads remaining stake

*

Read more
17 May 2024 15:52

London close: Stocks recoup some earlier losses

(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.

Read more
17 May 2024 11:52

LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady

(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.

Read more
17 May 2024 09:03

TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion

(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.

Read more
17 May 2024 08:56

LONDON MARKET OPEN: FTSE 100 lacklustre as Wall Street rally ends

(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.

Read more
17 May 2024 08:39

GSK raises $1.5 bln from sale of remaining Haleon stake

May 17 (Reuters) - British drugmaker GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Haleon to institutional investors.

Read more
17 May 2024 07:42

LONDON BRIEFING: Land Securities ups dividend; GSK sells Haleon stake

(Alliance News) - Stocks in London are called to open lower, as investors wait for an inflation reading from the eurozone later this morning.

Read more
17 May 2024 07:29

GSK raises £1.25bn from sale of remaining Haleon stake

(Sharecast News) - GSK said on Friday that it has sold its remaining 4.2% stake in consumer health business Haleon, which it spun off in July 2022.

Read more
16 May 2024 17:33

FTSE 100 ends lower on disappointing corporate updates, BT Group soars

BT Group up after CEO aims for more than double free cash flow

*

Read more
16 May 2024 17:13

TOP NEWS: GSK to sell remaining holding in spin-off Haleon

(Alliance News) - GSK PLC on Thursday said it intends to sell its remaining stake in Haleon PLC, the consumer healthcare firm it spun out almost two years ago.

Read more
16 May 2024 17:02

GSK to sell entire 4.2% remaining stake in Haleon

(Sharecast News) - GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.